1. Prosensa Completes Enrollment in Natural History Study of Duchenne Muscular Dystrophy

    Posted on June 25, 20141:54 pm

          Leiden, The Netherlands, June 25, 2014 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced the successful completion of enrollment in its prospective Natural History Study designed to increase the understanding of Duchenne muscular dystrophy (DMD). Read more »

  2. Cure Duchenne and the Duchenne Therapy Network Form Partnership to Provide Training to Physical Therapists and Duchenne Families

    Posted on June 17, 20145:54 pm

    CureDuchenne is pleased to announce a partnership with the Duchenne Therapy Network to provide training to physical therapists as well as Duchenne families and caregivers about specialized care for Duchenne patients. Duchenne is a progressive muscle-wasting disease that has no approved treatment or cure. Consistent physical therapy is one of the most important pieces of Read more »

  3. CureDuchenne Media Statement Regarding Prosensa Announcement of Regulatory Path Forward for Drisapersen as a Potential Treatment for DMD

    Posted on June 3, 20144:32 pm

          CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy, issued the following statement today regarding the announcement by Prosensa Holding N.V. (NASDAQ: RNA) that the United States Food and Drug Administration (FDA) has outlined a regulatory path forward, under an accelerated approval pathway, for Read more »